T. Hatziioannou

SARS-CoV-2 spike glycosylation affects function and neutralization sensitivity

This study examines how SARS-CoV-2 spike glycosylation affects viral function and neutralization sensitivity to antibodies.

Human anti-ACE2 monoclonal antibodies as pan-sarbecovirus prophylactic agents

The paper develops human monoclonal antibodies targeting the ACE2 receptor to block infection by SARS-CoV-2 and related sarbecoviruses, showing broad efficacy against variants and no adverse effects on ACE2 function.

Antigen presentation dynamics shape the response to emergent variants like SARS-CoV-2 Omicron strain after multiple vaccinations with wild type strain

The paper shows that antigen presentation dynamics after multiple vaccinations influence the immune response to SARS-CoV-2 Omicron by shaping B cell responses and antibody targeting of epitopes.

Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape

The paper shows that epistasis reduces the genetic barrier for SARS-CoV-2 variants to escape broadly neutralizing antibodies by enabling resistance through combinations of mutations.

Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection

This study compares memory B cell responses after Delta and Omicron BA.1 breakthrough infections versus mRNA vaccine doses, finding that Delta infection boosts overall memory B cell potency and breadth, while Omicron infection only enhances strain-specific responses.

Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens

This study compares humoral immune responses to different SARS-CoV-2 vaccination regimens, finding differences in antibody and memory B cell responses and neutralizing breadth against variants.

Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine

This study compares memory B cell responses after single-dose Ad26.COV2.S and mRNA vaccines, finding lower quantities but comparable neutralizing quality in Ad26.COV2.S recipients.

Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose

This study shows that a third mRNA vaccine dose increases the potency and breadth of SARS-CoV-2 neutralizing antibodies, particularly against the Omicron variant, through the expansion and evolution of memory B cells.

Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins

The paper identifies conserved neutralizing epitopes on the N-terminal domain of SARS-CoV-2 spike proteins using NTD-specific probes and characterizes antibodies that neutralize multiple variants.

High genetic barrier to escape from human polyclonal SARS-CoV-2 neutralizing antibodies

This study shows that multiple neutralizing epitopes in SARS-CoV-2 spike proteins are targeted by polyclonal antibodies, and 20 mutations can confer resistance, but vaccinated and infected individuals' plasma neutralizes these resistant variants and diverse sarbecoviruses.

Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination

This study examines memory B cell evolution 5 months after mRNA vaccination in naive individuals, finding increased neutralizing activity but no further breadth or potency, and higher overall plasma neutralizing potency compared to natural infection.

Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year

This study shows that convalescent individuals with or without vaccination maintain neutralizing activity and memory B cells against SARS-CoV-2 for up to one year, with vaccination enhancing breadth and potency against variants.

Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies

The paper identifies two class 4 anti-RBD antibodies from COVID-19 donors that broadly neutralize zoonotic sarbecoviruses and SARS-CoV-2 variants with high potency.

Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2

This paper presents a large repertoire of high-affinity nanobodies against SARS-CoV-2 Spike protein with potent neutralization properties and resistance to viral variants.

Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies

The paper maps mutations in SARS-CoV-2 spike RBD that escape binding by three antibody classes and finds that plasma escape maps closely resemble those of a single antibody class targeting site E484.

Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies

This study examines how somatic mutations in SARS-CoV-2 antibodies affect their neutralization potency, breadth, and resistance to escape mutations across six antibody lineages.

Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants

This paper isolates and characterizes nanobodies from camelids and engineered mice that neutralize SARS-CoV-2 variants through conserved epitopes and multimeric avidity.

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

This study examines antibody and memory B cell responses to mRNA vaccines against SARS-CoV-2 and assesses their effectiveness against emerging variants.

Bispecific antibody neutralizes circulating SARS-CoV-2 variants, prevents escape and protects mice from disease

A recombinant protein SARS-CoV-2 candidate vaccine elicits high-titer neutralizing antibodies in macaques.

This study evaluates a recombinant SARS-CoV-2 vaccine in macaques, showing that antigens from the RBD elicit high-titer neutralizing antibodies lasting over 20 weeks.

Evolution of Antibody Immunity to SARS-CoV-2

This study examines the evolution of antibody immunity to SARS-CoV-2 over time, finding that memory B cells evolve with increased potency and resistance to mutations.

Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo

This study evaluates the in vivo protective efficacy of SARS-CoV-2 monoclonal antibodies, finding that in vitro potency does not always predict in vivo activity and that effector function and combinations are critical for protection.

Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro

This study shows that secretory IgA, particularly dimers, are more potent than IgG in neutralizing SARS-CoV-2 in vitro, suggesting their importance for mucosal protection and vaccine design.

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

The paper shows SARS-CoV-2 variants resistant to neutralizing antibodies can be selected and are present in circulating populations, suggesting the need for combination antibody therapies.

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

The paper describes assays using pseudotyped and chimeric viruses to measure SARS-CoV-2 neutralizing antibody activity, showing correlation with authentic assays.

Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies

Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidity

This study investigates the interaction between SARS-CoV-2 Spike and ACE2, showing that dimeric ACE2 binds with high affinity to Spike and blocks viral entry, with limited intra-Spike avidity.

Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals

The paper analyzes antibody responses in convalescent individuals, finding low neutralizing titers but rare potent RBD-specific antibodies with broad antiviral potential.